Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutant Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT03349203
What this trial is testing

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Who this might be right for
EGF-R Positive Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07545213
What this trial is testing

Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis

Who this might be right for
Non-small Cell Lung CancerEGFR Mutant Advanced Non-small Cell Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine 27
Not applicableUnknownNCT04304638
What this trial is testing

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerStage III Non-small-cell Lung CancerEGFR Mutation-Related Tumors
Chinese Academy of Medical Sciences 450
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07822984
What this trial is testing

Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy

Who this might be right for
EGFR-mutant Non-small Cell Lung CancerSBRTNSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University 374
Testing effectiveness (Phase 2)Looking for participantsNCT04486833
What this trial is testing

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Who this might be right for
Carcinoma, Non-Small Cell Lung
Genprex, Inc. 158
Testing effectiveness (Phase 2)Ended earlyNCT02349633
What this trial is testing

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer 65
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07802834
What this trial is testing

Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC

Who this might be right for
EGFRLung Cancer (NSCLC)Non Small Cell Lung Cancer
Stanford University 42
Early research (Phase 1)UnknownNCT02321293
What this trial is testing

Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC

Who this might be right for
Lung Cancer
Lady Davis Institute 20
Early research (Phase 1)Study completedNCT07620951
What this trial is testing

Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China

Who this might be right for
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. 6
Not applicableNot Yet RecruitingNCT06786208
What this trial is testing

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Who this might be right for
Non Small Cell Lung Cancer
Henan Cancer Hospital 55
Not applicableUnknownNCT03764917
What this trial is testing

NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122717
What this trial is testing

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT01553942
What this trial is testing

Afatinib With CT and RT for EGFR-Mutant NSCLC

Who this might be right for
Lung Cancer
Massachusetts General Hospital 19
Early research (Phase 1)Ended earlyNCT03599518
What this trial is testing

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Daiichi Sankyo Co., Ltd. 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03831932
What this trial is testing

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
National Cancer Institute (NCI) 22
Early research (Phase 1)Study completedNCT05926180
What this trial is testing

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT03381274
What this trial is testing

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Who this might be right for
Carcinoma, Non-Small-Cell Lung
MedImmune LLC 43
Early research (Phase 1)Looking for participantsNCT04780568
What this trial is testing

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
Ohio State University Comprehensive Cancer Center 25
Not applicableUnknownNCT04778800
What this trial is testing

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Who this might be right for
NSCLCBrain MetastasesLeptomeningeal Metastasis
Henan Cancer Hospital 60
Early research (Phase 1)Ended earlyNCT02342353
What this trial is testing

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small Cell Lung CancerNonsmall Cell Lung CancerCarcinoma, Non-Small-Cell Lung
Washington University School of Medicine 8
Next Page